Abstracts

A Multiple Dose Study of Raltegravir (RAL) Formulations

Background: ISENTRESS (raltegravir) is an integrase strand transfer inhibitor indicated in combination with other anti-retroviral drugs for the treatment of human immunodeficiency virus (HIV-1) infection. ISENTRESS is currently marketed as a 400 mg oral compressed tablet (OCT) formulation of raltegravir given twice daily for a total daily dose of 800 mg. This study was conducted…

Optimisation of Intramuscular Sustained Release Nano-Formulations Using In Silico Modelling

Background: Intramuscular (IM) sustained release antiretroviral (ARV) nano-formulations (NFs) may provide pharmacological options to simplify regimens, reduce drug costs and improve adherence. Studies are currently on-going with injectable preparations for pre-exposure prophylaxis and treatment. The aim of this study was to simulate the pharmacokinetics (PK) of IM sustained release NFs using physiologically based pharmacokinetic (PBPK)…

In Vivo Effects of Solid Drug Nanoparticle and Conventional Efavirenz on Anxiogenesis in Rodents

Background: Efavirenz (EFV) has variable bioavailability and induces neurocognitive side effects, including anxiety. Recently we reported an EFV solid drug nanoparticle (SDN) formulation with pharmacological benefits. Here we investigated neurocognitive disturbances in rats using the elevated plus maze (EPM) after administration of a conventional or SDN formulation. In this model, anxiety is typically demonstrated by…

NanoART Facilitated HIV-1 Clearance by a Mixed-Lineage Kinase 3 Inhibitor

Background: Antiretroviral therapy (ART) has improved life quality and longevity for infected people. However, despite ART viral replication continues, albeit at low levels. Eradication of infection remains the major goal of HIV scientists and clinicians alike. Recently, a novel mixed-lineage kinase-3 (MLK3) inhibitor (URMC-099) with promising immune and neural modulatory activities was found. Surprisingly, the…

Macrophage Targeted Nanomedicines for Mycobacterial Infections

Background: Mycobacterium tuberculosis (MTB) is a common co-morbid HIV-associated infection. Complex drug regimens and microbial resistance underlie an alarming increase of infected people that now exceeds three million worldwide. The needs for access to simplified treatment regimens are of immediate need. This can be achieved by the development of long-acting cell and tissue targeted nanoformulated…

A Novel Anti-HIV Particle Provides Sustained Plasma and Cell Drug Levels in Lymph Nodes in Primates

Background: We have reported previously that an anti-HIV drug Indinavir bound to lipid nanoparticles (LNP) provide pH responsive release and extended plasma drug exposure and accumulation in lymph nodes in primates after subcutaneous dosing. The goal of this study is to develop and evaluate a HIV drug combination intended for a maximal suppression of residual…

Modulation of Natural Killer Cell Activity by Simian Immunodeficiency Virus Peptides

Background: Natural killer (NK) cells recognize and kill virus-infected cells without prior antigenic stimulation. This recognition is achieved in part through the loss of interactions between inhibitory killer-cell immunoglobulin-like receptors (KIRs) on NK cells and their MHC class I ligands on virus-infected cells. MHC class I-bound peptides can affect NK cell activation by stabilizing or…

Low Social Rank Prior to SIV or SHIV Infection Associates with Higher Viral Load in Chronic Infection

Background: The tempo of disease progression in HIV-infected humans and SIV-infected macaques is quite variable among individuals, with high levels of virus replication predicting shorter survival. Prolonged exposure to stress may alter immune system function even in the absence of HIV or SIV infection, and disruptions in housing environment, a known stress stimulus, shorten survival…

Obesity or Hypertension at ART Initiation and Outcomes Amongst HIV Patients in South Africa

Background: Aging, antiretroviral therapy (ART) and HIV infection itself have all been associated with increasing rates of chronic comorbidities in HIV patients but there are limited data on chronic disease risk factors and HIV treatment outcomes in resource-limited settings. We evaluated the association between high body mass index (BMI) or hypertension at ART initiation and…